Abstract
Vulvovaginal candidiasis (VVC) is one of the most common infections in
women. It is one of the most common fungal infections with Candida albicans (C.
albicans) as the major causative agent in humans. C. albicans is an opportunistic fungal
pathogen and a normal colonizer of the intestinal mucosa, oral cavity, and vulvovaginal
tract [1]. Overgrowth of the fungus followed by epithelial invasion and immune cell
infiltration leads to inflammatory symptoms such as vaginal itching, burning, and pain.
These clinical representations reduce the quality of life and cause high costs in the
global health system [2]. It is known that the fungus-glucan is highly immunoreactive
[3] and that β-glucan masking by mannan can inhibit the recognition and killing of
fungi by macrophages [4-6]. The aim of this study was to evaluate the ability of β-
glucan to protect against C. albicans vaginal infection.
Keywords: β-glucan, Beta Glucan, Vaginal Candidiasis, Vulvovaginal Candidiasis
Related Journals
Current Clinical Pharmacology
Current Cancer Therapy Reviews
Current Nanomedicine
Current Psychopharmacology
Drug Delivery Letters
Letters in Drug Design & Discovery
Recent Advances in Anti-Infective Drug Discovery
Coronaviruses
Applied Drug Research, Clinical Trials and Regulatory Affairs
Anti-Infective Agents
Related Books
Bioactive Phytochemicals: Drug Discovery to Product Development
Biologically Active Natural Products from Asia and Africa: A Selection of Topics
Endocannabinoids: Molecular, Pharmacological, Behavioral and Clinical Features
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Postbiotics: Science, Technology and Applications
Solubility, Delivery and ADME Problems of Drugs and Drug-Candidates
The Pharmaceutical Scientist Guide to Solution Kinetic Models Mathematical Description and Applications
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Pharmaceutical Chemistry and Production: An Introductory Textbook
